INTERVIEW: Heptares-Powered Sosei’s CEO-Elect On What Happens Next
This article was originally published in PharmAsia News
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology firm Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.
Register for our free email digests: